Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).
Messina C, Ferreri AJ, Govi S, Bruno-Ventre M, Gracia Medina EA, Porter D, Radford J, Heo DS, Park HY, Pro B, Jayamohan J, Visco C, Scarfò L, Zucca E, Gospodarowicz M, Christie D; International Extranodal Lymphoma Study Group (I.E.L.S.G.). Messina C, et al. Among authors: visco c. Br J Haematol. 2014 Mar;164(6):834-40. doi: 10.1111/bjh.12714. Epub 2014 Jan 2. Br J Haematol. 2014. PMID: 24383942 Free article.
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma.
Tecchio C, Nadali G, Scapini P, Bonetto C, Visco C, Tamassia N, Vassilakopoulos TP, Pangalis GA, Calzetti F, Nardelli B, Roschke V, Gottardi M, Zampieri F, Gherlinzoni F, Facchetti F, Pizzolo G, Cassatella MA. Tecchio C, et al. Among authors: visco c. Br J Haematol. 2007 Jun;137(6):553-9. doi: 10.1111/j.1365-2141.2007.06615.x. Br J Haematol. 2007. PMID: 17539776 Free article.
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, Stelitano C, Caracciolo F, Di Renzo N, Angrilli F, Carella AM, Capodanno I, Barbolini E, Galimberti S, Federico M. Merli F, et al. Among authors: visco c. Br J Haematol. 2012 Feb;156(3):346-53. doi: 10.1111/j.1365-2141.2011.08958.x. Epub 2011 Dec 7. Br J Haematol. 2012. PMID: 22145911 Free article. Clinical Trial.
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O'Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Møller MB, Wu L, Medeiros LJ, Young KH. Visco C, et al. Haematologica. 2013 Feb;98(2):255-63. doi: 10.3324/haematol.2012.066209. Epub 2012 Aug 28. Haematologica. 2013. PMID: 22929980 Free PMC article.
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Kahl BS, Winter JN, Xu W, Li J, Go RS, Li Y, Piris MA, Møller MB, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH. Xu-Monette ZY, et al. Among authors: visco c. Blood. 2012 Nov 8;120(19):3986-96. doi: 10.1182/blood-2012-05-433334. Epub 2012 Sep 5. Blood. 2012. PMID: 22955915 Free PMC article.
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH. Hu S, et al. Among authors: visco c. Blood. 2013 Apr 4;121(14):2715-24. doi: 10.1182/blood-2012-10-461848. Epub 2013 Jan 23. Blood. 2013. PMID: 23343832 Free PMC article.
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH. Hu S, et al. Among authors: visco c. Blood. 2013 May 16;121(20):4021-31; quiz 4250. doi: 10.1182/blood-2012-10-460063. Epub 2013 Feb 28. Blood. 2013. PMID: 23449635 Free PMC article.
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, Piris MA, Møller MB, Wu L, Wang M, Ramos KS, Medeiros LJ, Young KH. Li Y, et al. Among authors: visco c. Blood. 2013 May 30;121(22):4529-40. doi: 10.1182/blood-2012-12-471722. Epub 2013 Mar 20. Blood. 2013. PMID: 23515929 Free PMC article.
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study).
Mian M, Capello D, Ventre MB, Grazio D, Svaldi M, Rossi A, Tsang R, Gospodarowicz MK, Oldani E, Federico M, Luminari S, Marcheselli L, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Gutierrez-Garcia G, Busetto M, Visco C, Fiegl M, Rossi D, Gaidano G, Cavalli F, Zucca E, Rambaldi A, Cortelazzo S; International Extranodal Lymphoma Study Group (IELSG). Mian M, et al. Among authors: visco c. Ann Hematol. 2014 Feb;93(2):221-231. doi: 10.1007/s00277-013-1856-4. Epub 2013 Aug 20. Ann Hematol. 2014. PMID: 23959436
225 results